Intralesional Cidofovir for the Management of Refractory Cutaneous Verrucae: a Review of Applications and Opportunities

Overview

Journal Ther Adv Infect Dis

Publisher Sage Publications

Specialty Infectious Diseases

Date 2023 Apr 14

PMID 37056449

Authors

William C Lau

Charles B Lau

Jason E Frangos

Vinod E Nambudiri

Affiliations

Soon will be listed here.

Abstract

Viral warts - manifestations of cutaneous infection by human papilloma virus - can be a significant physical and emotional burden for patients when common treatments fail, particularly for individuals who are immunocompromised or with multiple lesions. Cidofovir, an antiviral agent typically used for the treatment of cytomegalovirus infection, has emerged as an alternative treatment option for viral warts when administered topically or intralesionally. In this review, we highlight the scientific rationale, published evidence, and practical clinical uses of intralesional cidofovir for the management of cutaneous warts as well as ongoing questions requiring further research and exploration of this emerging therapy for refractory verrucae.

Citing Articles

A humanized neutralizing antibody protects against human adenovirus type 7 infection in humanized desmoglein-2 and CD46 double-receptor transgenic mice.

Zhou C, Liao X, Zhou Z, Mo C, Yang Y, Liao H Virol J. 2024; 21(1):294.

PMID: 39548554 PMC: 11568553. DOI: 10.1186/s12985-024-02572-y.

HPV Infections-Classification, Pathogenesis, and Potential New Therapies.

Mlynarczyk-Bonikowska B, Rudnicka L Int J Mol Sci. 2024; 25(14).

PMID: 39062859 PMC: 11277246. DOI: 10.3390/ijms25147616.

Cutaneous Applications of the Antiviral Drug Cidofovir: A Review.

Poppens M, Ruci A, Davis J J Clin Med. 2024; 13(9).

PMID: 38730991 PMC: 11084884. DOI: 10.3390/jcm13092462.

References

Hoesli R, Thatcher A, Hogikyan N, Kupfer R . Evaluation of Safety of Intralesional Cidofovir for Adjuvant Treatment of Recurrent Respiratory Papillomatosis. JAMA Otolaryngol Head Neck Surg. 2020; 146(3):231-236. PMC: 7018395. DOI: 10.1001/jamaoto.2019.4029. View

Anshelevich E, Barbieri J, Kovarik C . Intralesional cidofovir for treatment of recalcitrant warts in both immunocompetent and immunocompromised patients: A retrospective analysis of 58 patients. J Am Acad Dermatol. 2020; 84(1):206-207. DOI: 10.1016/j.jaad.2020.04.118. View

Leung A, Barankin B, Leong K, Hon K . Penile warts: an update on their evaluation and management. Drugs Context. 2019; 7:212563. PMC: 6302884. DOI: 10.7573/dic.212563. View

Zabawski Jr E, Cockerell C . Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects. J Am Acad Dermatol. 1998; 39(5 Pt 1):741-5. DOI: 10.1016/s0190-9622(98)70046-5. View

Kaul S, Kaur I, Jakhar D, Edigin E, Caldito E . The diverse methods of bleomycin delivery in cutaneous warts: A literature review. Dermatol Ther. 2020; 34(1):e14401. DOI: 10.1111/dth.14401. View

dallOglio F, DAmico V, Nasca M, Micali G . Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol. 2012; 13(2):73-96. DOI: 10.2165/11594610-000000000-00000. View

Tjon Pian Gi R, Ilmarinen T, van den Heuvel E, Aaltonen L, Andersen J, Brunings J . Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients. Eur Arch Otorhinolaryngol. 2013; 270(5):1679-87. DOI: 10.1007/s00405-013-2358-7. View

Zabawski Jr E . A review of topical and intralesional cidofovir. Dermatol Online J. 2001; 6(1):3. View

Oh B . Cidofovir Intralesional Injection for Recalcitrant Common Warts: A Comparison with Sodium Tetradecyl Sulfate Intralesional Injection. Ann Dermatol. 2021; 32(4):273-279. PMC: 7992651. DOI: 10.5021/ad.2020.32.4.273. View

10.

Moore E, Kovarik C . Intralesional cidofovir for the treatment of a plantar wart. J Am Acad Dermatol. 2015; 73(1):e23-4. DOI: 10.1016/j.jaad.2015.02.1143. View

11.

Broganelli P, Chiaretta A, Fragnelli B, Bernengo M . Intralesional cidofovir for the treatment of multiple and recalcitrant cutaneous viral warts. Dermatol Ther. 2012; 25(5):468-71. DOI: 10.1111/j.1529-8019.2012.01477.x. View

12.

Fathi R, Tsoukas M . Genital warts and other HPV infections: established and novel therapies. Clin Dermatol. 2014; 32(2):299-306. DOI: 10.1016/j.clindermatol.2013.08.014. View

13.

Stragier I, Snoeck R, De Clercq E, van den Oord J, Van Ranst M, De Greef H . Local treatment of HPV-induced skin lesions by Cidofovir. J Med Virol. 2002; 67(2):241-5. DOI: 10.1002/jmv.2213. View

14.

Johnson J, Gangemi J . Selective inhibition of human papillomavirus-induced cell proliferation by (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Antimicrob Agents Chemother. 1999; 43(5):1198-205. PMC: 89133. DOI: 10.1128/AAC.43.5.1198. View

15.

Broekema F, Dikkers F . Side-effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2008; 265(8):871-9. PMC: 2441494. DOI: 10.1007/s00405-008-0658-0. View

16.

Ciconte A, Campbell J, Tabrizi S, Garland S, Marks R . Warts are not merely blemishes on the skin: A study on the morbidity associated with having viral cutaneous warts. Australas J Dermatol. 2003; 44(3):169-73. DOI: 10.1046/j.1440-0960.2003.00672.x. View

17.

Muse M, Stiff K, Glines K, Cline A, Feldman S . A review of intralesional wart therapy. Dermatol Online J. 2020; 26(3). View

18.

Lott D, Krakovitz P . Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis. Laryngoscope. 2009; 119(3):567-70. DOI: 10.1002/lary.20082. View

19.

Bonatti H, Aigner F, De Clercq E, Boesmueller C, Widschwendner A, Larcher C . Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl Int. 2007; 20(3):238-46. DOI: 10.1111/j.1432-2277.2006.00430.x. View

20.

Wanat K, Gormley R, Rosenbach M, Kovarik C . Intralesional cidofovir for treating extensive genital verrucous herpes simplex virus infection. JAMA Dermatol. 2013; 149(7):881-3. DOI: 10.1001/jamadermatol.2013.4014. View